Head-to-head comparisons of medication uses, side effects, warnings, and more.
Tremfya (guselkumab)
Entyvio (vedolizumab)
Tremfya (guselkumab)
Entyvio (vedolizumab)
Summary of Tremfya vs. Entyvio
Summary for Interleukin antagonist
Prescription only
Tremfya (guselkumab) is an injection for adults with certain inflammatory conditions. It helps treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. Tremfya (guselkumab) is a monoclonal antibody known as an interleukin antagonist. It calms your immune system to lower inflammation. The dosing schedule is every 1 or 2 months, depending on your condition and how far along you are in treatment. Side effects are upper respiratory infections, headache, and injection site reactions. There's also a risk of other infections and liver problems as long-term side effects.
Summary for Integrin antagonist
Prescription only
Entyvio, the brand name for vedolizumab, is an injection used to treat ulcerative colitis (UC) and Crohn's disease (CD) in adults. It belongs to a drug class called integrin antagonists that helps lower inflammation in the gut. Entyvio (vedolizumab) is an infusion that's given through the vein by a healthcare professional. After the first 2 doses, it's usually given every 2 months. If it works well, people can switch to injections under the skin every 2 weeks using prefilled syringes or pens. Side effects include headache, mild infections, and joint pain.